$114 Million is the total value of DAFNA Capital Management LLC's 66 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GLPG | GALAPAGOS NVspon adr | $4,241,000 | -0.7% | 66,068 | 0.0% | 3.73% | +25.2% | |
| XENE | XENON PHARMACEUTICALS INC | $3,959,000 | -4.9% | 514,091 | 0.0% | 3.48% | +19.9% | |
| DERM | DERMIRA INC | $2,997,000 | -10.3% | 98,800 | 0.0% | 2.63% | +13.1% | |
| PODD | INSULET CORP | $2,769,000 | -7.9% | 73,484 | 0.0% | 2.43% | +16.1% | |
| INSULET CORPnote 2.000% 6/1 | $2,457,000 | -1.0% | 2,250,000 | 0.0% | 2.16% | +24.9% | ||
| DSCI | DERMA SCIENCES INC | $1,839,000 | +11.3% | 353,718 | 0.0% | 1.62% | +40.4% | |
| SPNC | SPECTRANETICS CORP | $1,605,000 | -2.3% | 65,496 | 0.0% | 1.41% | +23.3% | |
| TNDM | TANDEM DIABETES CARE INC | $1,557,000 | -71.9% | 724,286 | 0.0% | 1.37% | -64.6% | |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $1,546,000 | +1.4% | 2,500,000 | 0.0% | 1.36% | +27.9% | ||
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $1,524,000 | -32.1% | 350,392 | 0.0% | 1.34% | -14.4% | |
| QURE | UNIQURE NV | $1,142,000 | -26.8% | 203,907 | 0.0% | 1.00% | -7.7% | |
| JNJ | JOHNSON AND JOHNSON | $1,083,000 | -2.4% | 9,400 | 0.0% | 0.95% | +23.0% | |
| STXS | STEREOTAXIS INC | $892,000 | -25.3% | 1,372,862 | 0.0% | 0.78% | -5.8% | |
| EXAC | EXACTECH INC | $864,000 | +1.1% | 31,636 | 0.0% | 0.76% | +27.6% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $722,000 | -38.7% | 101,841 | 0.0% | 0.63% | -22.7% | |
| ELOS | SYNERON MEDICAL LTD | $722,000 | +17.4% | 85,947 | 0.0% | 0.63% | +48.1% | |
| CGNT | COGENTIX MEDICAL INC | $710,000 | +10.4% | 353,482 | 0.0% | 0.62% | +39.3% | |
| IRONWOOD PHARMACEUTICALS INCdbcv 2.250% 6/1 | $690,000 | -3.8% | 600,000 | 0.0% | 0.61% | +21.4% | ||
| CNCE | CONCERT PHARMACEUTICALS INC | $689,000 | +1.8% | 66,968 | 0.0% | 0.60% | +28.2% | |
| MASI | MASIMO CORPORATION | $674,000 | +13.3% | 10,000 | 0.0% | 0.59% | +43.0% | |
| INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 added | $618,000 | -22.2% | 600,000 | 0.0% | 0.54% | -1.8% | ||
| PIRS | PIERIS PHARMACEUTICALS INC | $314,000 | -23.0% | 223,325 | 0.0% | 0.28% | -2.8% | |
| NEOS | NEOS THERAPEUTICS INC | $227,000 | -11.3% | 38,873 | 0.0% | 0.20% | +11.8% | |
| CYAD | CELYADadr | $222,000 | -25.0% | 12,528 | 0.0% | 0.20% | -5.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.